Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof inventions 04/09

20090111968 - Self-assembled proteins and related methods and protein structures: The present invention provides user-directed construction of novel specific homo- and hetero-dimeric, and multimeric assemblages of proteins. The present invention is comprised of gene sequences that transcribe peptide sequences that form links between proteins, where the peptide sequences produce a hook or loop which supports specific self-assembly of homo-dimers, hetero-dimers... Agent: Eckert Seamans Cherin & Mellott

20090111969 - Macrocyclic compounds as inhibitors of viral replication: The embodiments provide compounds of the general formulas I-XIX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an... Agent: Knobbe Martens Olson & Bear LLP

20090111970 - Canine and feline immunoregulatory proteins, nucleic acid molecules, and uses thereof: The present invention relates to canine interleukin-5 proteins; canine interleukin-5 nucleic acid molecules, including those that encode canine interleukin-5 proteins; to antibodies raised against such proteins; and to inhibitory compounds that regulate such proteins. The present invention also includes methods to identify and obtain such proteins, nucleic acid molecules, antibodies,... Agent: Sheridan Ross P.C.

20090111971 - Protein refolding agent and refolding method: A refolding agent and refolding method which make it possible to produce high-purity proteins in high productivity. The refolding agent includes a phosphorus-containing compound (A) and an oxycarbonyl group-containing compound (B). The refolding method includes the step of treating the unfolded protein with the refolding agent. As the compound (A),... Agent: Dennison, Schultz & Macdonald

20090111972 - Novel hemopoietin receptor protein, nr12: A novel hemopoietin receptor gene (NR12) was successfully isolated by extracting motifs conserved among the amino acid sequences of known hemopoietin receptors and by using the predicted sequence. The NR12 gene encodes two forms of proteins, a transmembrane type and a soluble type. The expression of the NR12 gene was... Agent: Fish & Richardson PC

20090111973 - Sigirr dna and polypeptides: DNA encoding SIGIRR polypeptides and methods for using the encoded polypeptides are disclosed.... Agent: Marshall, Gerstein & Borun LLP

20090111974 - Treatment of liver cirrhosis and its complications: The present invention relates to the field of liver diseases, more particularly to the field of portal hypertension and liver cirrhosis. The invention relates to the use of molecules which can inhibit the binding of placental growth factor (PIGF) to its receptor (VEGFR-1), such as monoclonal antibodies, for the manufacture... Agent: Nixon & Vanderhye, PC

20090105448 - Methods for the specific preparation of lysobactin fragments: The invention relates to methods for the targeted production of lysobactin derivatives by combined chemical and enzymatic modifications. In particular, the invention relates to method for preparing lysobactin fragment 4-11 by chemical reduction and cleavage of the resultant product by chymotrypsin.... Agent: Morrison & Foerster LLP

20090105449 - Novel ph dependent adhesive peptides: A novel peptide adhesive motif is described that requires no receptor or cross-links to achieve maximal adhesive strength. Several peptides with different degrees of adhesive strength have been designed and synthesized using solid phase chemistries. All peptides contain a common hydrophobic core sequence flanked by positively or negatively charged amino... Agent: Medlen & Carroll

20090105451 - Use of aqueous wettable hydrophobic chromatographic media for the purification of peptides, and other biomolecules: The use of hydrophobic coated metal oxides particles or film for the purifications of proteins, peptides or other biomolecules. This process eliminates two steps of purification as compared to silica or polymer based particles.... Agent: Ashok K. Shukla

20090105450 - Use of modified metal oxides for enrichment of phosphopeptides: Use of modified metal oxides for the purification and enrichment of negatively charged biomolecules such as peptides, proteins, DNA, RNA, Lipids, carbohydrates, glyco molecules. These metal oxides are modified in such a way that the density of the Lewis acid group is reduced due to modification.... Agent: Ashok K. Shukla

20090105452 - Non-fluorescent quencher compounds and biomolecular assays: e

20090105453 - Interleukin-9 receptor mutants: This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173... Agent: Morgan Lewis & Bockius LLP

20090105454 - Prophylactic/therapeutic agent for cancer: A compound or its salt that regulates (preferably inhibits) the activity of a protein comprising the same or substantially the same amino acid sequence as represented by SEQ ID NO: 1, a compound or its salt that regulates (preferably inhibits) the expression of a gene for the protein, an antisense... Agent: Edwards Angell Palmer & Dodge LLP

20090105455 - Purified interleukin-15/fc fusion protein and preparation thereof: The present invention relates to a process for purifying an interleukin-15/Fc fusion protein from a composition, which process comprises a) applying the composition to an affinity chromatography column and eluting a first IL-15/Fc eluate from the column and b) applying the eluate of step a) to an ion exchange chromatography... Agent: Clark & Elbing LLP

20090105456 - Porous keratin construct and method of making the same: The invention relates to a porous keratin construct material comprising keratin protein for use in wound healing applications. The porous keratin construct is capable of bio-absorbing into a wound to promote wound healing. The rate at which the construct bio-absorbs into the wound may be controlled altered by controlling the... Agent: Holland & Hart, LLP

20090105457 - Novel hemopoietin receptor protein, nr12: A novel hemopoietin receptor gene (NR12) was successfully isolated by extracting motifs conserved among the amino acid sequences of known hemopoietin receptors and by using the predicted sequence. The NR12 gene encodes two forms of proteins, a transmembrane type and a soluble type. The expression of the NR12 gene was... Agent: Fish & Richardson PC

20090105458 - Novel hemopoietin receptor protein, nr12: A novel hemopoietin receptor gene (NR12) was successfully isolated by extracting motifs conserved among the amino acid sequences of known hemopoietin receptors and by using the predicted sequence. The NR12 gene encodes two forms of proteins, a transmembrane type and a soluble type. The expression of the NR12 gene was... Agent: Fish & Richardson PC

20090105459 - Novel hemopoietin receptor protein, nr12: A novel hemopoietin receptor gene (NR12) was successfully isolated by extracting motifs conserved among the amino acid sequences of known hemopoietin receptors and by using the predicted sequence. The NR12 gene encodes two forms of proteins, a transmembrane type and a soluble type. The expression of the NR12 gene was... Agent: Fish & Richardson PC

20090105460 - Antibody and inhibitor, and transfection method or kit using them: The present invention provides a monoclonal antibody which specifically binds to human Toll-like receptor 3 and inhibits production of type 1 interferon. It also provides an inhibitor which (a) suppresses a double-stranded RNA-mediated immune response in a cell which expresses Toll-like receptor 3 that recognizes the double-stranded RNA and produces... Agent: Nixon & Vanderhye, PC

20090105461 - Calicheamicin conjugates: Anti-Lewis Y antibodies are described. Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described.... Agent: Wyeth Patent Law Group

20090105462 - Glycosylated erythropoietin: The invention relates to erythropoietin having certain O-linked and/or N-linked oligosaccharide structures.... Agent: Synageva Biopharma Corp.

20090105463 - Compositions of and methods of using oversulfated glycosaminoglycans: The invention relates, in part, to compositions comprising glycosaminoglycans, fragments of glycosaminoglycans or glycosaminoglycan fractions. The compositions provided can be used in various methods of modulating FGF and/or VEGF activity. The method can be in vitro or in vivo methods. Therefore, the invention also relates, in part, to methods of... Agent: Wolf Greenfield & Sacks, P.C.

20090105464 - Physiologically active polypeptide and dna: A physiologically active polypeptide derived from human brain and a DNA fragment comprising the base sequence encoding the polypeptide are disclosed. The polypeptide possesses excellent smooth muscle relaxation activity, diuretic or natriuretic activity, and vasodepressor activity, and is thus useful as a medicine for curing circulation diseases, e.g. cardiac edema,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090105465 - Protein purification using hcic and ion exchange chromatography: The present invention provides methods for purifying proteins. In particular, the methods employ a two-step non-affinity chromatography process without the use of an in-process tangential flow filtration step.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090099334 - Metastin derivatives and use thereof: The present invention provides stable metastin derivatives having excellent biological activities (a cancer metastasis suppressing activity, a cancer growth suppressing activity, a gonadotrophic hormone secretion stimulating activity, sex hormone secretion stimulating activity, etc.). By substituting the constituent amino acids of metastin with specific amino acids in the metastin derivative of... Agent: Edwards Angell Palmer & Dodge LLP

20090099335 - Polyomavirus diagnostic reagents: The present invention relates to HLA-A*02-restricted cellular epitopes within the VP1 polypeptide of human polyomaviruses, which are useful as diagnostic reagents for virus infection. Preferred peptides correspond to amino acids residues 107-116, 108-116 and 44-52 of BKV VP1, and are processed in vivo in natural infection with BKV. Effector T... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090099336 - Ca6 antigen-specific cytotoxic conjugate and methods of using the same: Cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the... Agent: Sughrue Mion, PLLC

20090099337 - S-nitroso group-containing albumin, method for production, and anticancer agent: The present invention provides an S-nitroso group-containing albumin, comprising an S-nitroso group introduced to at least one lysine in the amino acid sequence for albumin. The S-nitro group has been introduced into a lysine in the S-nitroso group-containing albumin of the invention to allow more S-nitroso groups to be included... Agent: Sughrue Mion, PLLC

20090099338 - Novel protein highly producing recombinant animal cell, method for preparing the same, and method for mass-producing protein using the same: A gene encoding a production amount-potentiating factor is introduced into an animal cell to transform the cell. Alternatively, a protein production gene and the gene encoding the production amount-potentiating factor are introduced into the animal cell to transform the cell. Herein, as the production amount potentiating factor, there is used... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090099339 - Antibody and antibody fragments for inhibiting the growth of tumors: Chimerized and humanized versions of anti EGF receptor antibody 225 and fragments thereof for treatment of tumors.... Agent: Imclon Lerner, David, Littenberg, Krumholz & Mentlik, LLP

20090099340 - Reagents for the detection of protein phosphorylation in carcinoma signaling pathways: The invention discloses 214 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human carcinoma, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among... Agent: Simona Levi-minzi, Ph.d. General Counsel

20090099341 - Heparanase specific molecular probes and their use in research and medical applications: A variety of heparanase specific molecular probes which can be used for research and medical applications including diagnosis and therapy. Specific applications include the use of a heparanase specific molecular probe for detection of the presence, absence or level of heparanase expression; the use of a heparanase specific molecular probe... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090099342 - Process for preparing composite particles, composite particles obtained, and their use in a diagnostic test: The invention relates to a process for preparing composite particles by encapsulation of an organic-phase-depleted emulsion by polymerization, said emulsion consisting of droplets of inorganic emulsion comprising an organic phase and inorganic nanoparticles distributed in said organic phase, characterized in that the polymerization is carried out using, as the polymerization... Agent: Oliff & Berridge, PLC

20090099343 - Isolation of pathogenic prions: Peptide reagents that interact preferentially with the PrPsc form of the prion protein are described. Methods of using the reagents for isolation and purification of the PrPsc isoform are described.... Agent: Novartis Vaccines And Diagnostics Inc.

20090099344 - Reducing protein a leaching during protein a affinity chromatography: A method for reducing leaching of protein A during protein A affinity chromatography is described which involves reducing temperature or pH of, or by adding one or more protease inhibitors to, a composition that is subjected to protein A affinity chromatography.... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090099345 - Carbon-based solid acid, catalyst comprising the solid acid, and reaction using the solid acid as catalyst: The organic substance to be used as the raw material for preparing the solid acid is preferably a saccharide having β1-4 glycosidic bond (e.g. cellulose) or lignin. Amylose is also suitable as the raw material. Examples of the reaction for which the solid catalyst can be used include hydration of... Agent: Weingarten, Schurgin, Gagnebin & Lebovici LLP

20090093612 - Amide-substituted xanthene dyes: The present invention provides amide-substituted xanthene fluorescent dyes and reagent for the introduction of phosphonate or sulfo groups into the fluorescent dyes.... Agent: Townsend And Townsend And Crew, LLP

20090093613 - Treatment of tinnitus: The invention relates to the use of substances which are at least partly blocking one ionotropic acetylcholine receptor of the inner ear and/or a calcium-activated potassium channel functionally associated with said acetylcholine receptor of the inner ear for the manufacturing of a pharmaceutical composition or medicament for the treatment of... Agent: Gary M. Nath The Nath Law Group

20090093614 - Self-assembled proteins and related methods: The present invention provides user-directed construction of novel specific homo- and hetero-dimeric, and multimeric assemblages of proteins. The present invention is comprised of a family of peptide sequences that forms links between proteins, where the peptide sequences produce a hook or loop which supports specific self-assembly of dimers of the... Agent: Eckert Seamans Cherin & Mellott

20090093615 - Metastin derivatives and use thereof: The present invention provides stable metastin derivatives having excellent biological activities (a cancer metastasis suppressing activity, a cancer growth suppressing activity, a gonadotrophic hormone secretion stimulating activity, sex hormone secretion stimulating activity, etc.). By substituting the constituent amino acids of metastin with specific amino acids in the metastin derivative of... Agent: Edwards Angell Palmer & Dodge LLP

20090093616 - In-solution activation of factor vii: The present invention is directed to a method for activation of Factor VII to FVIIa in solution.... Agent: Maxygen, Inc. Intellectual Property Department

20090093617 - Crystals of whole antibodies and fragments thereof and methods for making and using them: This invention relates to crystals of whole antibodies and fragments thereof, and formulations and compositions comprising such crystals. More particularly, methods are provided for the crystallization of high concentrations of whole antibodies, and fragments thereof, in large batches, and for the preparation of stabilized whole antibody crystals for use alone,... Agent: Lowrie, Lando & Anastasi, LLP

20090093618 - Streptavidin-biotin-link antibody-hapten system: The present invention provides antibodies comprising an antigen recognition domain that specifically binds to a metal chelate: mutant antibodies comprising a reactive site not present in the wild-type of the antibody, wherein the reactive site is in a position proximate to or within the antigen recognition domain; and methods of... Agent: Morgan, Lewis & Bockius LLP (sf)

20090093619 - Human t2r51 nucleic acid sequences and polypeptides: Newly identified mammalian taste-cell-specific G Protein-Coupled Receptors and the genes encoding said receptors are described. Specifically, T2R taste G Protein-Coupled Receptors that are believed to be involved in bitter taste sensation, and the genes encoding the same, are described, along with methods for isolating such genes and for isolating and... Agent: Hunton & Williams LLP Intellectual Property Department

20090088553 - Bis-sulfhydryl macrocyclization systems: The present invention provides novel peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production.... Agent: Wilson Sonsini Goodrich & Rosati

20090088555 - 44 human secreted proteins: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20090088554 - Hdm2-inhibitor complexes and uses thereof: The present invention includes crystallized HDM2 peptides as well as descriptions of the X-ray diffraction patterns of the crystals. The diffraction patterns allow the three dimensional structure of HDM2 to be determined at atomic resolution so that ligand binding sites on HDM2 can be identified and the interactions of ligands... Agent: Philip S. Johnson Johnson & Johnson

20090088556 - Fusion antigen used as vaccine and method of making them: Fusion antigen used as vaccine and method of making them. The method includes: (1) selecting a segment of a virus protein sequence that contains a least one epitope; (2) engineering a DNA fragment encoding the selected segment of the virus protein; (3) inserting the DNA fragment into a Pseudomonas Exotoxin... Agent: Ipc Intellectual Property Connections, Inc.